Table 3.

Characteristics and outcomes of UCBT recipients who developed CMV disease (n = 10)

Age, y	Prophylaxis	Diagnosis	Conditioning regimen	No. donors	aGVHD grade, days	Time to CMV reactivation, days	Viral load at first reactivation, copies/mL	Time to CMV disease, days	Sites of CMV disease	Out-come
Early disease (days 0-100)
42	Standard	AML	Cy + Flu + TBI (1320 cGy)	2	2 (21)	57	3354	92	GI	Alive
64	Standard	AML	Cy + Flu + TBI (1320 cGy)	2	2 (34)	18	22 000	34	Lung	Dead
23	Standard	ALL	Cy + Flu + ATG + TBI (200 cGy)	2	3 (15)	17*	35	17*	Lung	Alive
28	Standard	AML	CY + Flu + TBI (1320 cGy)	2	NE	21*	63	33	Disseminated	Dead
21	Standard	ALL	Cy + Flu + TBI (1320 cGy)	2	NE	8*	6000	11*	GI	Dead
42	Standard	ALL	Cy + Flu + TBI (1320 cGy)	2	2 (35)	3*	100	66	GI	Alive
1	Intensive	Hystiocytosis	Campath + Mel + Flu	1	0	3*	47	11*	Lung	Alive
53	Intensive	AML	Treo + Flu + TBI (200 cGy)	2	NE	-	-	42†	Lung	Dead
Late disease (days 101-365)
54	Standard	AML	Cy + Flu + ATG, TBI (200 cGy)	1	0	21	1053	191	Lung	Dead
2	Standard	AML	Cy + Flu + TBI (1320 cGy)	2	3 (10)	8*	3200	165	Lung	Alive

ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATG, antithymocyte globulin; Cy, cyclophosphamide; Flu, fludarabine; GI, gastrointestinal; Intensive, intensive prophylactic strategy; Mel, melphalan, NE, not evaluable; Standard, standard prophylactic strategy; TBI, total body irradiation; and UCBT, umbilical cord blood transplantation.

^*Complication developed preengraftment.

^†Developed early relapse.